Neurogene (NGNE) Non-Current Debt (2013)

Neurogene (NGNE) posted Non-Current Debt of $2.0 million for Q4 2013.

Neurogene (NGNE) Non-Current Debt (2013) Analysis & Trends

Neurogene's Non-Current Debt history runs 1 years deep, the most recent figure standing at $2.0 million for Q4 2013.

Quarterly Non-Current Debt changed N/A year-over-year to $2.0 million in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $2.0 million (changed N/A YoY) and the FY2013 annual result came in at $2.0 million, changed N/A from the prior year.
Non-Current Debt was $2.0 million for Q4 2013 at Neurogene.
Across five years, Non-Current Debt topped out at $2.0 million in Q4 2013 and bottomed at $2.0 million in Q4 2013.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Neurogene	17.50 Mn	17.50 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2013	2.04 Mn